SEARCH
 







Novozymes Biopharma Technologies



Innovative science and a strong IP portfolio drives Novozymes’ technologies platforms.

As the world leaders in yeast based protein expression, we bring over 45 years worth of experience in industrial scale recombinant protein production to the biopharmaceutical industry.

Protein expression

Our expression technology can be readily manipulated in direct response to our customers’ requirements and we have demonstrated its ability to express an extensive range of proteins, representing many classes of biotherapeutics.

 

› Yeast based expression
The gold standard in microbial protein expression.

 

› Antibody fragment expression
Unique and versatile expression technology delivering cost effective, fully functional antibody fragments with proven half-life extension.

Albumin fusions

albufuse™, albumin fusion technology is the molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability.

 

› Albufuse™ technology
Molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability.

 

Visit our Info center

For product brochures or other product related information, visit our Info center.

For enquiries or ordering information
Contact us

Copyright © 2008 Novozymes.